Antithrombotic Therapy in Coronary Embolism: A Multicenter Study
Thrombosis and Haemostasis · 23.10.2026
DOI: 10.1055/a-2980-6716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 23.10.2026. Verfasst von Alberto Vera und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario de Navarra, Department of Cardiology, Navarra, Spain, Pamplona. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Coronary embolism (CE) is an uncommon cause of acute myocardial infarction, and the optimal postdischarge antithrombotic strategy remains uncertain. Retrospective multicenter study including patients with definite or probable CE. Three groups of patients were identified: (1) requiring specific management, (2) with atrial fibrillation (AF), and (3) with no indication for oral anticoagulation (OAC). The latter two groups were further classified according to the antithrombotic treatment received, and long-term outcomes (composite of recurrent CE, stroke, systemic embolism, cardiovascular or all-cause death, and major bleeding at 5 years) were subsequently evaluated. A total of 489 patients were considered. Among 189 patients with AF, 85 received direct oral anticoagulants (DOAC) and 104 vitamin K antagonists (VKAs). VKA users showed a higher rate of the composite endpoint compared with DOACs (40 vs. 18%, p < 0.001), with the difference primarily driven by all-cause mortality. In multivariable analysis, VKA therapy remained independently associated with worse outcomes (hazard ratio [HR]: 1.9, 95% confidence interval [CI]: 1.02–3.5; p = 0.04). In the 182 patients without an indication for anticoagulation, 115 received antiplatelet therapy and 67 received OAC. Those treated with OAC had a higher incidence of the composite outcome (16 vs. 7%, p = 0.049), with the difference primarily driven by all-cause mortality. Multivariable analysis confirmed OAC as an independent predictor of adverse prognosis (HR: 3.4; 95% CI: 1.2–9.7; p = 0.02). In patients with CE, stratification based on underlying etiology and embolic risk before hospital discharge might serve as a decision-making approach for determining optimal antithrombotic strategies and improved clinical outcomes.
Autor:innen und Institutionen
- Hospital Universitario de Navarra, Department of Cardiology, Navarra, Spain, Pamplona.
- Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), D…
- Université de Lorraine, CHRU-Nancy, Department of Cardiology, Grand Est, France, Nancy.
- Hospital Universitario Clínico San Carlos, Department of Cardiology, Spain, Madrid.
- Hospital Universitario de la Princesa, Department of Cardiology, Spain, Madrid.
- Hospital General Universitario Dr. Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Department of Cardiology, Spain, Alicante.
Zitieren
APA
Vera, A., Jover, E., Varlot, J., Pozo-Osinalde, E., Vilches, L., Ferrer, R. A., Lanaspa, A., Navarro, A., Jiménez, P., Méndez, C. J., Álvarez, R., Margolles, L. C., Gonzalo, N., Ferrer, M. A., Moreno, A., Filloy, C. G., Sanz-García, A., Álvarez, V., Alfonso, F., …, & Popovic, B. (2026). Antithrombotic Therapy in Coronary Embolism: A Multicenter Study. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2980-6716
Vancouver
Vera A, Jover E, Varlot J, Pozo-Osinalde E, Vilches L, Ferrer RA, et al. Antithrombotic Therapy in Coronary Embolism: A Multicenter Study. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2980-6716
BibTeX
@article{Vera2026,
author = {Vera, Alberto and Jover, Eva and Varlot, Jeanne and Pozo-Osinalde, Eduardo and Vilches, Lidia and Ferrer, Raquel A and Lanaspa, Arturo and Navarro, Adela and Jiménez, Pilar and Méndez, César J and Álvarez, Rut and Margolles, Laura C and Gonzalo, Nieves and Ferrer, María A and Moreno, Anai and Filloy, Carlos García and Sanz-García, Ancor and Álvarez, Virgina and Alfonso, Fernando and Ruiz-Quevedo, Valeriano and Popovic, Batric},
title = {Antithrombotic Therapy in Coronary Embolism: A Multicenter Study},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2980-6716}
}
EUVIMED